Vertex Pharmaceuticals, Inc [VRTX] stock is trading at $447.09, up 0.45%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRTX shares have gain 2.70% over the last week, with a monthly amount drifted -11.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on May 07, 2025, when Wolfe Research downgraded its rating to a Peer Perform. Previously, Leerink Partners downgraded its rating to Market Perform on May 06, 2025, and kept the price target unchanged to $503. Canaccord Genuity upgraded its rating to a Hold and increased its price target to $424 on February 12, 2025. Canaccord Genuity upgraded its rating to a Hold. Wells Fargo downgraded its rating to Equal Weight for this stock on January 30, 2025, but kept the price target unchanged to $460. In a note dated December 20, 2024, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $600 to $535.
Vertex Pharmaceuticals, Inc [VRTX] stock has fluctuated between $377.85 and $519.88 over the past year. Currently, Wall Street analysts expect the stock to reach $484 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $447.09 at the most recent close of the market. An investor can expect a potential return of 8.26% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] reported sales of 11.04B for the trailing twelve months, which represents a growth of 2.19%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.06 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 443.49 points at the first support level, and at 439.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 449.95, and for the 2nd resistance point, it is at 452.82.
Ratios To Look Out For
For context, Vertex Pharmaceuticals, Inc’s Current Ratio is 2.65. Also, the Quick Ratio is 2.29, while the Cash Ratio stands at 1.24. Considering the valuation of this stock, the price to sales ratio is 10.40, the price to book ratio is 6.96.
Transactions by insiders
Recent insider trading involved LR 2019 Benefit Trust, Director, that happened on May 21 ’25 when 170.0 shares were purchased. Director, SR 2019 Benefit Trust completed a deal on May 21 ’25 to buy 170.0 shares. Meanwhile, EVP, Chief Scientific Officer ALTSHULER DAVID sold 52.0 shares on May 15 ’25.
